These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 17211046)

  • 1. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
    Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian rhythms, melatonin and depression.
    Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
    Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction between the internal clock and antidepressant efficacy.
    Racagni G; Riva MA; Popoli M
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M; Prica C
    Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of agomelatine's antidepressant efficacy: the key points.
    Eser D; Baghai TC; Möller HJ
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.